Reactives CAS DOT SHHC Sources Number Chemical Name
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Transport of Dangerous Goods
ST/SG/AC.10/1/Rev.16 (Vol.I) Recommendations on the TRANSPORT OF DANGEROUS GOODS Model Regulations Volume I Sixteenth revised edition UNITED NATIONS New York and Geneva, 2009 NOTE The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. ST/SG/AC.10/1/Rev.16 (Vol.I) Copyright © United Nations, 2009 All rights reserved. No part of this publication may, for sales purposes, be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying or otherwise, without prior permission in writing from the United Nations. UNITED NATIONS Sales No. E.09.VIII.2 ISBN 978-92-1-139136-7 (complete set of two volumes) ISSN 1014-5753 Volumes I and II not to be sold separately FOREWORD The Recommendations on the Transport of Dangerous Goods are addressed to governments and to the international organizations concerned with safety in the transport of dangerous goods. The first version, prepared by the United Nations Economic and Social Council's Committee of Experts on the Transport of Dangerous Goods, was published in 1956 (ST/ECA/43-E/CN.2/170). In response to developments in technology and the changing needs of users, they have been regularly amended and updated at succeeding sessions of the Committee of Experts pursuant to Resolution 645 G (XXIII) of 26 April 1957 of the Economic and Social Council and subsequent resolutions. -
Voorblad Cyanamide.Fm
Cyanamide and calcium cyanamide (CAS No: 420-04-2, 156-62-7) Health-based Reassessment of Administrative Occupational Exposure Limits Committee on Updating of Occupational Exposure Limits, a committee of the Health Council of the Netherlands No. 2000/15OSH/133 The Hague, November 9, 2004 Preferred citation: Health Council of the Netherlands: Committee on Updating of Occupational Exposure Limits. Cyanamide and calcium cyanamide; Health-based Reassessment of Administrative Occupational Exposure Limits. The Hague: Health Council of the Netherlands, 2004; 2000/15OSH/133. all rights reserved 1 Introduction The present document contains the assessment of the health hazard of cyanamide and calcium cyanamide by the Committee on Updating of Occupational Exposure Limits, a committee of the Health Council of the Netherlands. The first draft of this document was prepared by MA Maclaine Pont, MSc (Wageningen University and Research Centre, Wageningen, the Netherlands). In August 2000, literature was searched in the databases Toxline, Medline, and Chemical Abstracts, starting from 1981, 1966, and 1992, respectively, and using the following key words: cyanamide, carbimide, carbodiimide, cyanoamine, cyanogen amide, cyanogen nitride, hydrogen cyanamide, N- cyanoamine, calcium cyanamide, 156-62-7, 420-04-2, and 6860-10-2. Data of unpublished studies were generally not taken into account. Exceptions were made for studies that were summarised and evaluated by the German MAK committee (Gre02). The final literature search was carried out in September 2003. In October 2003, the President of the Health Council released a draft of the document for public review. Comments were received from the following individuals and organisations: A Aalto (Ministery of Social Affairs and Health, Tampere, Finland). -
US EPA Inert (Other) Pesticide Ingredients
U.S. Environmental Protection Agency Office of Pesticide Programs List of Inert Pesticide Ingredients List 3 - Inerts of unknown toxicity - By Chemical Name UpdatedAugust 2004 Inert Ingredients Ordered Alphabetically by Chemical Name - List 3 Updated August 2004 CAS PREFIX NAME List No. 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 74-86-2 Acetylene 3 141754-64-5 Acrylic acid, isopropanol telomer, ammonium salt 3 25136-75-8 Acrylic acid, polymer with acrylamide and diallyldimethylam 3 25084-90-6 Acrylic acid, t-butyl ester, polymer with ethylene 3 25036-25-3 Acrylonitrile-methyl methacrylate-vinylidene chloride copoly 3 1406-16-2 Activated ergosterol 3 124-04-9 Adipic acid 3 9010-89-3 Adipic acid, polymer with diethylene glycol 3 9002-18-0 Agar 3 61791-56-8 beta- Alanine, N-(2-carboxyethyl)-, N-tallow alkyl derivs., disodium3 14960-06-6 beta- Alanine, N-(2-carboxyethyl)-N-dodecyl-, monosodium salt 3 Alanine, N-coco alkyl derivs. -
Alcohol-Medication Interactions: the Acetaldehyde Syndrome
arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Borja-Oliveira, J Pharmacovigilance 2014, 2:5 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000145 Review Article Open Access Alcohol-Medication Interactions: The Acetaldehyde Syndrome Caroline R Borja-Oliveira* University of São Paulo, School of Arts, Sciences and Humanities, São Paulo 03828-000, Brazil *Corresponding author: Caroline R Borja-Oliveira, University of São Paulo, School of Arts, Sciences and Humanities, Av. Arlindo Bettio, 1000, Ermelino Matarazzo, São Paulo 03828-000, Brazil, Tel: +55-11-30911027; E-mail: [email protected] Received date: August 21, 2014, Accepted date: September 11, 2014, Published date: September 20, 2014 Copyright: © 2014 Borja-Oliveira CR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Medications that inhibit aldehyde dehydrogenase when coadministered with alcohol produce accumulation of acetaldehyde. Acetaldehyde toxic effects are characterized by facial flushing, nausea, vomiting, tachycardia and hypotension, symptoms known as acetaldehyde syndrome, disulfiram-like reactions or antabuse effects. Severe and even fatal outcomes are reported. Besides the aversive drugs used in alcohol dependence disulfiram and cyanamide (carbimide), several other pharmaceutical agents are known to produce alcohol intolerance, such as certain anti-infectives, as cephalosporins, nitroimidazoles and furazolidone, dermatological preparations, as tacrolimus and pimecrolimus, as well as chlorpropamide and nilutamide. The reactions are also observed in some individuals after the simultaneous use of products containing alcohol and disulfiram-like reactions inducers. -
(VI) and Chromium (V) Oxide Fluorides
Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 1976 The chemistry of chromium (VI) and chromium (V) oxide fluorides Patrick Jay Green Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Chemistry Commons Let us know how access to this document benefits ou.y Recommended Citation Green, Patrick Jay, "The chemistry of chromium (VI) and chromium (V) oxide fluorides" (1976). Dissertations and Theses. Paper 4039. https://doi.org/10.15760/etd.5923 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. All ABSTRACT OF THE TllESIS OF Patrick Jay Green for the Master of Science in Chemistry presented April 16, 1976. Title: Chemistry of Chromium(VI) and Chromium(V) Oxide Fluorides. APPROVEO BY MEMBERS OF THE THESIS CO'"o\l TIEE: y . • Ii . ' I : • • • • • New preparative routes to chromyl fluoride were sought. It was found that chlorine ironofluoride reacts with chromium trioxide and chromyl chlo ride to produce chromyl fluoride. Attempts were ~ade to define a mechan ism for the reaction of ClF and Cr0 in light of by-products observed 3 and previous investigations. Carbonyl fluoride and chromium trioxide react to fom chro·yl fluoride and carbo:i dioxide. A mechanism was also proposed for this react10n. Chromium trioxide 11itl\ l~F6 or WF5 reacts to produce chromyl fluoride and the respective oxide tetrafluoride. 2 Sulfur hexafluoride did not react with Cr03. -
United Nations LAWS and REGULATIONS FRANCE
E/NL.1950/9-16 1 March 1950 United Nations LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE CONVENTION OF 13 JULY 1931 FOR LIMITING THE MANUFACTURE AND REGULATING THE DISTRIBUTION OF NARCOTIC DRUGS AS AMENDED BY THE PROTOCOL OF 11 DECEMBER 1946 FRANCE COMMUNICATED BY THE GOVERNMENT OF FRANCE Lake Success, New York, 1950 Note by the Secretary-General In accordance with Article 21 of the Convention of 13 July 1931 for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, as amended by the Protocol of 11 December 1946, the Secretary-General has the honour to communicate here• after the texts of regulations. Ori gina1: English E/NL.1950/9 COMPOSITION OF PART II OF THE SCHEDULES OF POISONOUS SUBSTANCES* 1he Minister of Public Health and Population, •Considering the amended Act of 19 July 1845, Considering the Decree of 19 November 1943, and in particular Article 1 of the said Decree, Orders as follows: Article 1 The following substances shall be included in Schedule A, Part II: Arsenious oxide and arsenic acid Hydrocyanic acid Aconite (leaves, roots, extract and tincture) Aconitine and its salts Adrenaline Alkaloids of opium, their salts and their derivatives, other than those specifically mentioned in Schedule B Apomorphine and its salts Arecoline and its salts Arsenates and arsenites Metallic arsenic (cobalt) Atropine and its salts Belladonna (leaves, roots, powder and extract) Benzoate of mercury Dichloride of mercury Bi-iodide of mercury Bromo form Methyl bromide Brucine and its salts Cantharides (whole, powder and tincture) Cantharidin and its salts Chloroform Chloropicrin Hemlock (fruit, powder and extract) Codeine and its salts Colchicine and its salts Colchicum (seeds and extract) Conine and its salts Convalla toxin Indian berry The poisonous substances classified in the Codex without legal authority as "toxic" substances or as substances "to be kept separately" are not listed here. -
S J. Braz. Chem. Soc., Vol. 22, No. 2, 352-358, 2011
J. Braz. Chem. Soc., Vol. 22, No. 2, 352-358, 2011. Printed in Brazil - ©2011 Sociedade Brasileira de Química S 0103 - 5053 $6.00+0.00 Short Report Synthesis and Antileishmanial Activity of New 1-Aryl-1H-Pyrazole-4- Carboximidamides Derivatives Maurício S. dos Santos,a Adriana O. Gomes,a Alice M. R. Bernardino,*,a Marcos C. de Souza,a Misbahul A. Khan,b Monique A. de Brito,c Helena C. Castro,d Paula A. Abreu,d Carlos R. Rodrigues,e Rosa M. M. de Léo,f Leonor L. Leonf and Marilene M. Canto-Cavalheirof aPrograma de Pós-Graduação em Química Orgânica and dLABioMol, GCM - IB, Universidade Federal Fluminense, Outeiro de São João Baptista, 24020-150 Niterói-RJ, Brazil bChemistry Department, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan cLaboratório de Química Medicinal Computacional, Faculdade de Farmácia, Universidade Federal Fluminense, 24241-000 Niterói-RJ, Brazil eFaculdade de Farmácia, ModMolQSAR, Universidade Federal do Rio de Janeiro, 24020-150 Rio de Janeiro-RJ, Brazil fLaboratório de Bioquímica de Tripanosomatídeos, IOC, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro-RJ, Brazil A quimioterapia para as leishmanioses, doenças causadas por protozoários do gênero Leishmania, ainda permanece ineficiente em diversos tratamentos. Portanto, existe a necessidade de pesquisa por novos fármacos. Nesse trabalho, foram sintetizados derivados 1-aril-1H-pirazol- 4-carboximidamidas, avaliadas as atividades leishmanicida e os efeitos citotóxicos in vitro, e realizado um estudo de relação estrutura-atividade (REA) com a série de compostos. O composto 2 apresentou um perfil de atividade que pode ser melhorado através de estratégias de modificação molecular da química medicinal. -
Pneumocystis Pneumonia and Disseminated
1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss. -
Tatp, Tnt, and Rdx)
University of Central Florida STARS Electronic Theses and Dissertations, 2004-2019 2010 Development Of Reductive Metal Systems For The Degradation Of Energetic Compounds (tatp, Tnt, And Rdx) Rebecca L. Albo University of Central Florida Part of the Chemistry Commons Find similar works at: https://stars.library.ucf.edu/etd University of Central Florida Libraries http://library.ucf.edu This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more information, please contact [email protected]. STARS Citation Albo, Rebecca L., "Development Of Reductive Metal Systems For The Degradation Of Energetic Compounds (tatp, Tnt, And Rdx)" (2010). Electronic Theses and Dissertations, 2004-2019. 1552. https://stars.library.ucf.edu/etd/1552 DEVELOPMENT OF REDUCTIVE METAL SYSTEMS FOR THE DEGRADATION OF ENERGETIC COMPOUNDS (TATP, TNT, AND RDX) by REBECCA L. FIDLER ALBO B.S. University of Central Florida, 2005 A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Chemistry in the College of Sciences at the University of Central Florida Orlando, Florida Summer Term 2010 Major Professor: Cherie L. Geiger © 2010 Rebecca Albo ii ABSTRACT Triacetone triperoxide (TATP), a cyclic peroxide explosive, is frequently used by terrorists and amateur chemists due to the ease of synthesis and the availability of reagents. TATP is extremely sensitive to shock, heat, and friction thus a safe and rapid method for treating TATP is needed. The major objective of this dissertation was to develop in situ methodologies that could safely degrade TATP in various field situations. -
Chlorine Trifluoride
MATERIAL SAFETY DATA SHEET Prepared to U.S. OSHA, CMA, ANSI and Canadian WHMIS Standards 1. PRODUCT IDENTIFICATION CHEMICAL NAME; CLASS: CHLORINE TRIFLUORIDE SYNONYMS: Chlorine Fluoride CHEMICAL FAMILY NAME: Halogen Fluoride FORMULA: ClF3 Document Number: 20026 PRODUCT USE: Use as a fluorinator; for cutting oil-well tubes; reprocessing reactor fuels, as an oxidizer in propellants. SUPPLIER/MANUFACTURER'S NAME: AIR LIQUIDE AMERICA CORPORATION ADDRESS: 2700 Post Oak Drive Houston, TX 77056-8229 EMERGENCY PHONE: CHEMTREC: 1-800-424-9300 BUSINESS PHONE: General MSDS Information 1-713/896-2896 Fax on Demand: 1-800/231-1366 2. COMPOSITION and INFORMATION ON INGREDIENTS CHEMICAL NAME CAS # mole % EXPOSURE LIMITS IN AIR ACGIH OSHA TLV STEL PEL STEL IDLH OTHER ppm ppm ppm ppm ppm Chlorine Trifluoride 7790-91-2 > 99% NE 0.1, C NE 0.1, C 20 NIOSH REL: 0.1 C ppm DFG MAK: 0.1 ppm, C Maximum Impurities < 1% None of the trace impurities in this product contribute significantly to the hazards associated with the product. All hazard information pertinent to this product has been provided in this Material Safety Data Sheet, per the requirements of the OSHA Hazard Communication Standard (29 CFR 1910.1200) and State equivalents standards. NE = Not Established C = Ceiling Limit See Section 16 for Definitions of Terms Used. NOTE: all WHMIS required information is included. It is located in appropriate sections based on the ANSI Z400.1-1993 format. CHLORINE TRIFLUORIDE - ClF3 MSDS EFFECTIVE DATE: JUNE 1, 1998 PAGE 1 OF 9 3. HAZARD IDENTIFICATION EMERGENCY OVERVIEW: Chlorine Trifluoride is an extremely toxic, corrosive, water-reactive, oxidizing, colorless, liquefied gas, with a suffocating, sweet odor. -
WTR-Core Product Code SMI2337-1 SDS No
Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2015/830 SAFETY DATA SHEET SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1 Product identifier Product name WTR-Core Product code SMI2337-1 SDS no. SMI2337-1 Product type Paste 1.2 Relevant identified uses of the substance or mixture and uses advised against Use of the substance/ Analytical reagent that is mixed with activator to form a test kit. mixture For specific application advice see appropriate Technical Data Sheet or consult our company representative. 1.3 Details of the supplier of the safety data sheet Supplier BP Marine Limited Chertsey Road Sunbury-on-Thames Middlesex TW16 7LN United Kingdom E-mail address [email protected] 1.4 Emergency telephone number EMERGENCY Carechem: +44 (0) 1235 239 670 (24/7) TELEPHONE NUMBER SECTION 2: Hazards identification 2.1 Classification of the substance or mixture Product definition Mixture Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS] Not classified. Ingredients of unknown Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1% toxicity Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1% Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1% Ingredients of unknown Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic ecotoxicity environment: 1% See sections 11 and 12 for more detailed information on health effects and symptoms and environmental hazards. 2.2 Label elements Signal word No signal word. -
Lonza's Chemical Network Diketene and HCN Derivatives, Heterocycles
Lonza’s chemical network Diketene and HCN derivatives, heterocycles and basic chemicals catalog Pharma&Biotech Nutrition Agriculture MaterialsScience PersonalCare Diketene and HCN derivatives, heterocycles and basic chemicals catalog Content About Lonza 3 Introduction 4 Diketene / ketene derivatives 6 Esters 6 Arylides 7 Alkylamides 8 Pyrazolones 9 Dehydroacetic acid 9 Lonzamon monomers 10 Other diketene derivatives 10 HCN derivatives 12 Heterocycles 14 Basic chemicals 16 Others 17 Alphabetical index 18 About Lonza Lonza is the global leader in the production and support of active phar- From 1897 to the present day combining Swiss tradition with global maceutical ingredients both chemically and biotechnologically. Biophar- experience, the company has had an enterprising character, adapting maceuticals are one of the key growth drivers of the pharmaceutical and its offerings and services to the needs of customers and to changing biotechnology industries. technologies. Throughout our history, we have maintained a strong culture of performance, results and dependability that is valued by all Lonza has strong capabilities in large and small molecules, peptides, of our customers. amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza’s cracker in Visp is the back bone of a comprehensive fully back- Lonza is a leader in cell-based research, endotoxin detection and cell ward integrated chemical network. Our product portfolio consists of therapy manufacturing. Furthermore, the company is a leading provider HCN- and diketene derivatives as well as basic chemicals which are key of chemical and biotech ingredients to the nutrition, hygiene, preserva- raw materials and intermediates for many sophisticated applications.